1 Department of Endocrinology, University of Groningen, University Medical Center Groningen , Groningen, The Netherlands .
2 Department of Pediatric Endocrinology, Beatrix Children's Hospital, University of Groningen, University Medical Center Groningen , Groningen, The Netherlands .
Thyroid. 2017 Dec;27(12):1481-1489. doi: 10.1089/thy.2017.0383.
Whether pediatric patients with differentiated thyroid carcinoma (DTC) are at risk of developing treatment-related adverse effects on cardiac function is unknown. We therefore studied in long-term survivors of pediatric DTC the prevalence of cardiac dysfunction and atrial fibrillation in relation to treatment variables, and the association between cardiac dysfunction and plasma biomarkers.
In this nationwide prospective multicenter study, cardiac assessments were performed in 66 adult survivors of pediatric DTC (age at diagnosis ≤18 years and follow-up ≥5 years after diagnosis) treated in the Netherlands between 1970 and 2009. Assessment included echocardiography, plasma biomarkers (N-terminal pro-brain natriuretic peptide, high-sensitive troponin-T, galectin-3), and 24-hour Holter electrocardiography. Echocardiographic measurements were compared with retrospective data of 66 sex- and age-matched unaffected Dutch controls. Diastolic dysfunction was defined as an early diastolic septal and/or lateral tissue velocity (e') less than 2 SD of mean age-adjusted reference data.
The survivors (86.4% women) had at DTC diagnosis a median age of 16 years. Median follow-up was 17 years. Left ventricular ejection fraction <50% was found in one survivor, and median global longitudinal systolic strain was near normal. Diastolic dysfunction was present in 14 asymptomatic survivors (21.2%). Overall, diastolic function of survivors was lower compared with controls (e'mean 14.5 versus 15.8 cm/s, P = 0.006). Older attained age and higher waist circumference were associated with decreased diastolic function, whereas thyrotropin levels and cumulative administered radioiodine dose were not. In survivors, biomarkers were not associated with diastolic dysfunction; atrial fibrillation was not observed.
While systolic function is unaffected, diastolic dysfunction is frequently observed in asymptomatic long-term survivors of pediatric DTC, which may suggest early cardiac aging.
患有分化型甲状腺癌(DTC)的儿科患者是否存在治疗相关心脏功能不良的风险尚不清楚。因此,我们研究了荷兰在 1970 年至 2009 年间治疗的 66 例儿科 DTC 长期幸存者的心脏功能障碍和心房颤动的发生率与治疗变量的关系,以及心脏功能障碍与血浆生物标志物之间的关系。
在这项全国性前瞻性多中心研究中,对 66 例荷兰儿童分化型甲状腺癌(诊断时年龄≤18 岁,诊断后随访≥5 年)成年幸存者进行了心脏评估。评估包括超声心动图、血浆生物标志物(N 末端脑利钠肽前体、高敏肌钙蛋白 T、半乳糖凝集素-3)和 24 小时动态心电图。超声心动图测量值与 66 名性别和年龄匹配的未受影响的荷兰对照者的回顾性数据进行了比较。舒张功能障碍定义为舒张早期室间隔和/或侧壁组织速度(e')小于平均年龄校正参考数据的 2 个标准差。
幸存者(86.4%为女性)在 DTC 诊断时的中位年龄为 16 岁。中位随访时间为 17 年。一名幸存者的左心室射血分数<50%,中位整体纵向收缩应变接近正常。14 名无症状幸存者存在舒张功能障碍(21.2%)。总的来说,幸存者的舒张功能低于对照组(e'平均值 14.5 与 15.8cm/s,P=0.006)。年龄较大和腰围较大与舒张功能下降有关,而促甲状腺激素水平和累积给予的放射性碘剂量与舒张功能下降无关。在幸存者中,生物标志物与舒张功能障碍无关;未观察到心房颤动。
虽然收缩功能不受影响,但儿科 DTC 长期无症状幸存者常出现舒张功能障碍,这可能表明存在早期心脏老化。